Mime Biosciences is a biotechnology company developing ultra-high-concentration, long-acting subcutaneous biologic therapies that achieve high drug loads in standard injection volumes while maintaining optimal flow properties for convenient self-administration.
Mime's technology enables well-tolerated subcutaneous injections, supports less frequent dosing, and has the potential to significantly improve treatment adherence for patients with chronic conditions.
The technology works across a range of biologics, including monoclonal, bispecific, and multi-specific antibodies, Fc-fusion proteins, antibody-drug conjugates, and antibody fragments.
It also enables high-concentration biologics formulations for intravitreal and intrathecal delivery, and other next-generation administration routes.
Our proprietary formulations are ultra-high-concentration, long-acting biologics with excellent stability, bioavailability, and pharmacokinetics that are equal to or exceed best-in-class benchmarks.
This technology enables high drug loads in standard injection volumes, extended dosing intervals, favorable flow properties, and improved patient experience compared with intravenous infusions or frequent SC injections.
High drug loads in standard volumes with optimal flow properties.
Extended dosing intervals – quarterly or less – for patient convenience.
Excellent stability and pharmacokinetics that meet or exceed benchmarks.
Well-tolerated, self-administered injections as an alternative to current marketed intravenous infusions or frequent SC dosing.
Our product candidates are selected to support efficient and manageable development timelines by leveraging Mime's formulation capabilities and insights into disease pathways, enabling a focus on large patient populations with substantial remaining unmet need.
Mime's product candidates are engineered as fully human, ultra-high-concentration, long-acting subcutaneous biologic treatments. Each candidate targets a large indication with potential for label expansion into follow-on indications.
Mime partners with pharmaceutical and biotech companies to optimize their biologic therapies using our ultra-high-concentration, highly tolerable, long-acting formulation technology.
We engineer each biologic to meet defined attributes for concentration, stability, tolerability, and dosing interval — supporting subcutaneous self-administration and yielding a highly differentiated, competitively positioned, patient-friendly product profile.
The technology works across a range of biologics, including monoclonal, bispecific, and multi-specific antibodies, Fc-fusion proteins, antibody-drug conjugates, and antibody fragments.
It also enables high-concentration biologics formulations for intravitreal and intrathecal delivery, and other next-generation administration routes.
Our formulations offer potential for new patent protection that extends commercial life of established commercial or pipeline biologics.
Complete the form below to connect with a team member and share your development goals.